康诺亚生物医药科技有限公司总部位于成都，专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化，康诺亚于2021年7月8日在香港联合交易所主板上市。
Employees: 51-200
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | 3H Health ... | 3hhinvestm... |
Mentions in press and media 17
| Date | Title | Description |
| 13.09.2024 | Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults | CHENGDU, China, Sept. 13, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the new drug application for Stapokibart... |
| 29.08.2024 | Harbour BioMed and Keymed Biosciences: Navigating the Biopharmaceutical Landscape in 2024 | In the ever-evolving world of biopharmaceuticals, two companies stand out: Harbour BioMed and Keymed Biosciences. Both are charting ambitious paths through the complex terrain of drug development, showcasing resilience and innovation. Their... |
| 27.08.2024 | Keymed Biosciences Announces Interim Results for First Half of 2024 | CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM31... |
| 03.06.2024 | Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis | CHENGDU, China, June 3, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic derm... |
| 27.03.2024 | Keymed Biosciences Announces 2023 Annual Results and Business Updates | Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review. Advanced a Phase III clinical study of Stapokibart for... |
| 15.05.2023 | Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis | SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 23.02.2023 | Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901 | CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZen... |
| 18.01.2023 | Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM | CHENGDU, China, Jan. 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug ... |
Show more